Cargando…
Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
BACKGROUND: The ROS1 gene is a member of the “sevenless” subfamily of tyrosine-kinase insulin-receptor genes. ROS1-fusion rearrangement causes constitutive downstream signal transduction, with an oncogenic role in non-small-cell lung carcinoma (NSCLC). Fortunately, crizotinib, an ALK1 tyrosine-kinas...
Autores principales: | Mehta, Anurag, Saifi, Mumtaz, Batra, Ullas, Suryavanshi, M, Gupta, Kush |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047993/ https://www.ncbi.nlm.nih.gov/pubmed/32158297 http://dx.doi.org/10.2147/LCTT.S244366 |
Ejemplares similares
-
ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017) -
Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019) -
Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018) -
A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
por: Tachi, Hiroaki, et al.
Publicado: (2020) -
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
por: Zhang, Yongchang, et al.
Publicado: (2022)